We are building a strong biotech group focused on maximizing the expected return for our investors.

Discover our Strategy for 2028 and learn why it’s worth investing in NanoGroup.

About Us Strategy

We invite you to review the Management Board’s Report on Activities for 2025 (PL only) in its new, expanded format.

Report for 2025

News

See all
17.12.2025

Finalizing the Investment in Auxilius Pharma: A Strategic Step in Building a Biotechnology Group

NanoGroup S.A. announced today, December 17, 2025, the closing of a 7.5 million PLN investment in Auxilius Pharma S.A. as part of a funding …

16.12.2025

New investors among NanoGroup shareholders. Company raises more than PLN 10 million

NanoGroup S.A. signed an investment agreement for PLN 10.55 million with its main shareholder, Michal Lach, who simultaneously paid PLN 10.1 million. The funds …

21.11.2025

Secure innovation, predictable returns – new Development Strategy 2026 – 2028

NanoGroup S.A. has adopted a Development Strategy for 2026-2028, with the main goal of achieving a position in the TOP3 of Polish biotechnology g…

Milestones in building NanoGroup value

Project family Milestone Estimated date Okno partneringowe
NanOX Recovery Box Completion of biocompatibility study of the NanOX 4K Perfusion Set 2026 09 2027 Q1-Q2
Device audit by TÜV NORD 2026 10
Obtaining CE certification* 2027 Q1
NanOX 4 Kidney Start of non-GLP studies: isolated organs / autotransplantation 2026 09
Manufacturing of the first & second non‑GMP batch 2026 10
Completion of non‑GLP studies for the fluid – autotransplantation 2026 12
Completion of non‑GLP studies for the fluid – isolated organs 2027 01
Manufacturing of the first GMP batch 2027 01
Start of GLP-compliant autotransplantation study 2027 03
Completion of GLP-compliant autotransplantation study 2027 07
Submission to the Bioethics Committee for clinicat trial approval 2027 09
Aptamers Co-financing agreement 2026 11 TBA
Investment in Auxilius Pharma: AUX-001 Acquisition of Auxilius Pharma and its integration into the Capital Group 2026 12 2026 Q4
Completion of Phase 1b studies 2027 H1 2027 H2
*DEPENDENT ON THE NOTIFIED BODY

Milestones in building NanoGroup value

Project family Milestone Estimated date Partnering window
NanOX Recovery Box Completion of biocompatibility study of the NanOX 4K Perfusion Set 2026 09 2027 Q1-Q2
Device audit by TÜV NORD 2026 10 2027 Q1-Q2
Obtaining CE certification* 2027 Q1 2027 Q1-Q2
NanOX 4 Kidney Start of non-GLP studies: isolated organs / autotransplantation 2026 09 2027 Q1-Q2
Manufacturing of the first & second non‑GMP batch 2026 10 2027 Q1-Q2
Completion of non‑GLP studies for the fluid – autotransplantation 2026 12 2027 Q1-Q2
Completion of non‑GLP studies for the fluid – isolated organs 2027 01 2027 Q1-Q2
Manufacturing of the first GMP batch 2027 01 2027 Q1-Q2
Start of GLP-compliant autotransplantation study 2027 03 2027 Q1-Q2
Completion of GLP-compliant autotransplantation study 2027 07 2027 Q1-Q2
Submission to the Bioethics Committee for clinicat trial approval 2027 09 2027 Q1-Q2
Aptamers Co-financing agreement 2026 11 TBA
Investment in Auxilius Pharma: AUX-001 Acquisition of Auxilius Pharma and its integration into the Capital Group 2026 12 2026 Q4
Completion of Phase 1b studies 2027 H1 2027 H2
*DEPENDENT ON THE NOTIFIED BODY

Our leading projects

NanOX Recovery Box

The first dedicated normothermic kidney perfusion device on the market. The future gold standard.

NanOX 4 Kidney

A synthetic perfusion fluid dedicated to ex-vivo organ preservation. The first-in-class solution that maintains the key respiratory function of blood. A breakthrough in transplantation.

AUX-001

An improved form of Nicorandil for the treatment of chronic angina pectoris. Simplified FDA 505(b)(2) regulatory pathway, with priority target of the U.S. market.

Pipeline

Key pillars of NanoGroup’s development focused on critical, unmet medical needs.

Project family

Project

Status

Concept

Discovery

Pre-clinical

Respiratory Gas Transport System

NanOX 4 Kidney

In progress
  • Concept
  • Discovery
  • Pre-clinical

NanOX Recovery Box

In progress
  • Concept
  • Discovery
  • Pre-clinical

NanOX 4 Liver

Planned
  • Concept
  • Discovery
  • Pre-clinical

Blood Substitute – Humans

In progress, Completed
  • Concept
  • Discovery
  • Pre-clinical

Blood Substitute -Veterinary

Planned
  • Concept
  • Discovery
  • Pre-clinical

Polysaccharide Nanoparticle Platform

PolEpi

In progress
  • Concept
  • Discovery
  • Pre-clinical

Projects Based on Polysaccharide Nanoparticles

Planned
  • Concept
  • Discovery
  • Pre-clinical

Conjugates of dextran nanoparticles

TBA

In progress
  • Concept
  • Discovery
  • Pre-clinical

Radiotherapeutics

TBA

suspended
  • Concept
  • Discovery
  • Pre-clinical
Pipeline

Subsidiaries

nanoSanguis

Respiratory gas transport systems: Blood substitute and the NanoOX system.

nanoVelos

Polysaccharide Nanocapsules for Targeted Therapy

nanoTHEAradiopharmaceuticals

Radioisotopes for diagnostics and treatment

dotoMedical and aptamer platform

A patented method for aptamer manufacturing and its applications.

Career

Do you set ambitious scientific goals for yourself? Are you interested in participating in medical projects in the fields of biotechnology and nanotechnology?

NanoGroup is a platform for expertise and specialists united by the belief that breakthrough technologies addressing pressing global challenges can be created and developed in Poland.

If you’d like to join our team, get in touch with us!

Join the Team

Contact us

NanoGroup S.A.
ul. Rakowiecka 36
02-532 Warszawa
NIP: 5213757847
REGON: 365989838
KRS: 0000649960

District Court for the Capital City of Warsaw, XIII Commercial Division of the National Court Register, KRS number 0000649960. Share capital (fully paid) 32 813 238,00 PLN

Office
+48 604 741 303

Contact for media
PR Contact

pp-thumbnail